Table 1 Adolescent and young adult participant demographics
From: Reproductive health needs of adolescent and young adult women with pediatric rheumatic diseases
Cohort 1 | Cohort 2 | ||||
|---|---|---|---|---|---|
Consented AYA* (n = 27) | High School (n = 7) | Post High School (n = 2) | Conference Group (n = 11) | All AYA Participants** | |
Age (years +/− SD) | 17.3 ± 1.5 | 16.2 ± 1.0 | 18.0 ± 1.4 | 20.5 ± 2.5 | 18.3 ± 2.4 |
Ethnicity (%) | |||||
African-American/Black | 3 (11%) | 1 (14%) | 1 (5%) | ||
Asian | 1 (9%) | 1 (5%) | |||
White | 21 (78%) | 5 (71%) | 2 (100%) | 10 (91%) | 17 (85%) |
Hispanic/Latino | 1 (4%) | 1 (14%) | 1 (5%) | ||
Bi−/ Multi- racial | 2 (7%) | ||||
Disease *** | |||||
Juvenile idiopathic arthritis (JIA) | 19 (70%) | 5 (71%) | 1 (50%) | 7 (64%) | 13 (65%) |
Systemic lupus erythematosus/ Mixed connective tissue disease/ Juvenile dermatomyositis | 4 (15%) | 2 (29%) | 3 (27%) | 5 (25%) | |
Other (Specified below) | 4 (15%) | 2 (10%) | |||
Granulomatosis with polyangiitis | 1 (4%) | ||||
Orbital pseudotumor | 1 (4%) | ||||
Behçet’s disease | 1 (4%) | 1 (50%) | |||
Chronic recurrent multifocal osteomyelitis + JIA | 1 (9%) | ||||
Rheumatoid arthritis | 1 (4%) | ||||
Medications *** | |||||
Methotrexate (MTX) | 3 (11%) | 2 (29%) | 2 (10%) | ||
Leflunomide (LEF) | 2 (8%) | 2 (29%) | 2 (10%) | ||
Biologic only | 7 (26%) | 3 (27%) | 3 (15%) | ||
Combination (MTX/LEF+ biologic) | 9 (33%) | 5 (45%) ^^ | 5 (25%) | ||
Small molecule | 1 (9%) | 1 (5%) | |||
Mycophenolate | 2 (8%) | 2 (29%) | 2 (10%) | ||
Azathioprine | 1 (4%) | ||||
None / No medication listed | 3 (11%) | 1 (14%) | 2 (100%) | 2 (18%) | 5 (25%) |